硼中子俘获治疗复发高级别脑膜瘤的随机II期研究
本研究为研究者发起的随机II期试验,评估加速器硼中子俘获治疗(BNCT)对放疗后复发难治性高级别脑膜瘤的疗效与安全性。患者按2:1随机分配至BNCT组(12例)和对照组(6例),对照组进展后接受补救BNCT。主要终点独立评审无进展生存期(PFS)BNCT组14.4个月 vs 对照组1.4个月(P=0.0157),研究者评审PFS为14.7 vs 1.5个月(P=0.0002)。结论认为BNCT对难治性复发高级别脑膜瘤有效。
要点
- BNCT组独立评审中位PFS 14.4个月,对照组1.4个月,差异有统计学意义。
- 研究者评审中位PFS BNCT组14.7个月,对照组1.5个月,差异有统计学意义。
- BNCT组客观缓解率为27.3%,对照组5例进展后接受补救BNCT。
核心结论
- 硼中子俘获治疗对放疗后复发难治性高级别脑膜瘤有效,主要和次要终点PFS均较常规治疗显著改善。
研究设计与样本
- 研究者发起的随机对照II期试验,采用加速器BNCT系统,按2:1随机分配至BNCT组12例和对照组6例。
- 主要终点为独立第三方委员会判定的无进展生存期,次要终点为研究者判定PFS及BNCT组总生存。
- 对照组疾病进展后接受补救BNCT。
主要发现
- BNCT组WHO 3级3例、对照组2例,其余为WHO 2级。
- 主要终点中位PFS:BNCT组14.4个月(95%CI 7.9-26.4),对照组1.4个月(95%CI 1.0-9.0),log-rank P=0.0157。
- 次要终点中位PFS:BNCT组14.7个月(95%CI 7.6-22.8),对照组1.5个月(95%CI 1.0-9.0),log-rank P=0.0002。
- 对照组5例接受补救BNCT;BNCT组客观缓解率27.3%。
临床怎么用
- 对于X线治疗后复发的高级别脑膜瘤,可考虑加速器BNCT作为治疗选择。
- 治疗决策时可参考本试验中BNCT组较对照组显著延长的PFS数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade meningiomas (HGMs) recurring after X-ray treatment show a poor prognosis. We assessed the effectiveness and safety of boron neutron capture therapy (BNCT) in patients with refractory recurrent HGMs. METHODS: This phase II investigator-led randomized controlled trial utilized an accelerator-based BNCT system to treat refractory recurrent HGMs. Patients were randomly assigned in a 2:1 ratio to the BNCT (12 patients) and control (6 patients) arms. Progression-free survival (PFS) judged by an independent third-party committee was the primary endpoint and PFS judged by the investigators and overall survival of the BNCT arm were the secondary endpoints. The control arm received rescue BNCT if they show disease progression. RESULTS: Three and two patients with World Health Organization (WHO) grade 3 disease were assigned to the BNCT and control arms, respectively; the remaining patients had WHO grade 2 disease. Median PFS (primary endpoint) was 14.4 months (95% CI: 7.9-26.4) in the BNCT arm and 1.4 months (95% CI: 1.0-9.0) in the control arm. Median PFS (secondary endpoint) was 14.7 months (95% CI: 7.6-22.8) in the BNCT arm and 1.5 months (95% CI: 1.0-9.0) in the control arm. The differences were statistically significant (log-rank test, P = 0.0157 and P = 0.0002, respectively). Five patients in the control arm received rescue BNCT. The objective response rate in the BNCT arm was 27.3%. CONCLUSIONS: Boron neutron capture therapy is an effective treatment for refractory recurrent HGMs. Compared with conventional therapy, PFS in both primary and secondary endpoints were considerably improved.
引用
- Kashiwagi H, Wanibuchi M, Ikeda N, et al. Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study. Neuro Oncol. 2026. PMID: 41560342. doi:10.1093/neuonc/noaf279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。